Recent Updates in Juvenile Spondyloarthritis

Area of Science:

• Rheumatology
• Pediatric Rheumatology
• Immunology

Background:

• Spondyloarthritis encompasses disorders marked by enthesitis and axial skeletal involvement, typically starting before age 16 in its juvenile form.
• Joint involvement in juvenile spondyloarthritis is frequently asymmetric.
• The presence of bone marrow edema on noncontrast MRI of the sacroiliac joints aids in diagnosis.

Purpose of the Study:

• To summarize the key characteristics, diagnostic features, and therapeutic approaches for juvenile spondyloarthritis.
• To highlight the long-term implications and management strategies for this condition.

Main Methods:

• Review of current literature on juvenile spondyloarthritis.
• Analysis of diagnostic criteria, including MRI findings.
• Evaluation of established and emerging therapeutic options.

Main Results:

• The human leukocyte antigen B27 (HLA-B27) is the primary risk factor for axial disease.
• A significant proportion of patients continue to experience active disease into adulthood.
• Enthesitis and sacroiliitis are associated with increased pain and diminished quality of life.

Conclusions:

• Tumor necrosis factor inhibitors are the primary biologic treatment for spondyloarthritis.
• While IL-17 blockers show promise in adult spondyloarthritis, they lack FDA approval for this indication.
• Effective management requires early diagnosis and ongoing therapeutic strategies to mitigate long-term effects.